Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome

Background Liver‐selective thyromimetic agents could provide a new approach for treating dyslipidaemia. Methods We performed a multicentre, randomized, placebo‐controlled, double‐blind study to evaluate the efficacy and safety of eprotirome, a liver‐selective thyroid hormone receptor agonist, in 98...

Ausführliche Beschreibung